The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF) |
|---|---|
| Study Drug | Roscovitine |
| Type of Study Drug | Anti-infective and Anti inflammatory |
| Study Title | A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Causing Mutations With at Least One F508del-CFTR Mutation and Chronically Infected With Pseudomonas Aeruginosa, a Study Involving 36 CF Patients (24 Treated, 12 Controls). ROSCO-CF. |
| Study Phase | 2 |
| Study Sponsor | University Hospital Brest |
https://clinicaltrials.gov/ct2/show/NCT02649751 (link is external) | |
| Participating ECFS-CTN sites | Study in France Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | 18 Years and Older |